Every Form 4 that LivaNova PLC (LIVN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LIVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LIVN filings page.
LivaNova PLC (symbol: LIVN) is the issuer of record for a Form 4 filing submitted to the SEC. Liddy Anne M. reported acquisition or exercise transactions in this Form 4 filing.
LivaNova PLC (LIVN) reported that Chief Legal Officer Anne M. Liddy received a grant of 6,291 Restricted Stock Units (RSUs) on September 15, 2026 under the Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan. The RSUs vest 20% on March 30, 2027 (pro‑rated from the grant date), 40% on March 30, 2028, and 40% on March 30, 2029, and are subject to forfeiture before vesting. Each RSU represents a contingent right to receive one ordinary share of LivaNova PLC.
LivaNova PLC (LIVN) director Francesco Bianchi reported selling 3,500 Ordinary Shares on September 10, 2026 in an open-market transaction at a weighted-average price of $78.0092 per share, with individual sale prices ranging from $77.97 to $78.04. After this sale, he directly holds 4,434 Ordinary Shares, and no Rule 10b5-1 trading plan is reported for this transaction.
LivaNova PLC (LIVN) director Story Brooke reported selling 2,300 Ordinary Shares of the company on September 4, 2026 in a sale described as occurring in the open market or a private transaction at an average price of $81.42 per share. After this transaction, Brooke directly holds 7,488 Ordinary Shares, and no Rule 10b5-1 trading plan is reported.
LivaNova PLC (LIVN) director Francesco Bianchi reported selling 1,650 Ordinary Shares on August 31, 2026 in a sale classified as an open market or private transaction at $79.72 per share. After this transaction, he directly owns 7,934 Ordinary Shares, and no Rule 10b5-1 trading plan is reported.
LivaNova PLC Chief Innovation Officer Ahmet Tezel exercised 12,692 Stock Appreciation Rights at a base price of $52.68 per share, receiving the same number of ordinary shares. In connection with this, 8,589 shares were withheld to pay the SARs base price, 1,428 shares were withheld to satisfy tax liability, and 2,675 shares were sold in open-market transactions at a weighted-average price of $77.7355, within a range of $77.6684–$77.7900. The SARs were granted on June 15, 2024, vest over four years from June 15, 2025, and expire on June 15, 2034.
LivaNova PLC director Peter M. Wilver reported routine equity compensation activity involving restricted stock units (RSUs) and ordinary shares. On June 15, 2026, 4,042 RSUs vested and were settled into ordinary shares under the company’s 2025 Director Incentive Award Plan, and 486 ordinary shares were withheld to satisfy tax liabilities at a reference price of $79.70 per share. Following these transactions, he held 10,294 ordinary shares directly. On the same date, he received a new grant of 2,383 RSUs that each represent a right to receive one ordinary share and are scheduled to vest on June 15, 2027, subject to continued service and the plan terms. No open-market purchases or sales were reported.
LivaNova PLC director Todd C. Schermerhorn reported compensation-related equity activity involving restricted stock units (RSUs) and ordinary shares. On June 15, 2026, 4,042 RSUs were exercised into ordinary shares, and 486 shares were withheld at $79.70 per share to satisfy tax liabilities, leaving him with 12,619 ordinary shares directly owned.
On the same date, he received a new grant of 2,383 RSUs under LivaNova’s 2025 Director Incentive Award Plan, each representing a right to one ordinary share. These RSUs vest on June 15, 2027, subject to continued service and the plan’s terms. The tax withholding is an administrative disposition, not an open-market sale.
LivaNova PLC director Francesco Bianchi reported several equity transactions involving company ordinary shares and restricted stock units. He sold 1,200 ordinary shares in an open-market transaction at $80.19 per share and held 9,584 shares directly after the transactions. On the same date, vested restricted stock units were exercised, delivering 4,042 ordinary shares, with 486 shares withheld to satisfy tax liabilities at a price of $79.70 per share. Bianchi also received a new grant of 2,383 restricted stock units that each represent a right to receive one ordinary share, scheduled to vest on June 15, 2027 subject to continued service.
LivaNova PLC director Susan M. Podlogar reported compensation-related share activity tied to restricted stock units (RSUs). On June 15, 2026, vested RSUs were settled into 4,042 ordinary shares, and 486 shares were withheld at $79.70 per share to satisfy tax liabilities. Following these transactions, she directly owned 5,642 ordinary shares of LivaNova PLC.
On the same date, Podlogar also received a new grant of 2,383 RSUs under the company’s 2025 Director Incentive Award Plan. Each RSU represents one ordinary share, scheduled to vest on June 15, 2027, subject to continued service and the plan’s award agreement.
LivaNova PLC director Barry James Christopher reported equity compensation activity involving restricted stock units (RSUs) and ordinary shares. On June 15, 2026, 4,042 RSUs vested and were exercised into ordinary shares. Of these, 486 shares were withheld to cover tax liabilities, leaving him with 7,918 ordinary shares held directly after the tax-withholding disposition and 8,404 ordinary shares following all transactions. He also received a new grant of 2,383 RSUs under the company’s 2025 Director Incentive Award Plan, which are scheduled to vest on June 15, 2027, subject to continued service.
LivaNova PLC Chief Innovation Officer Ahmet Tezel reported routine equity compensation activity. On June 15, 2026, 2,965 restricted stock units vested and were settled in ordinary shares under the company’s incentive plan. To cover tax liability, 1,032 of these shares were withheld, a non-market disposition.
After these transactions, Tezel directly holds 6,090 ordinary shares and 5,931 unvested restricted stock units that remain subject to future vesting and forfeiture conditions. The filing reflects compensation-related equity vesting rather than open-market buying or selling.
Nygaard-Andersen Jette reported acquisition or exercise transactions in this Form 4 filing.
LivaNova PLC director Jette Nygaard-Andersen received a grant of 2,383 Restricted Stock Units (RSUs) as equity compensation. Each RSU represents a contingent right to receive one ordinary share of the company under the 2025 Director Incentive Award Plan and its award agreement.
The RSUs vest on June 15, 2027, subject to continued service through the vesting period and compliance with the plan terms. Following this grant, Nygaard-Andersen holds 2,383 RSUs directly, all tied to future delivery of ordinary shares if vesting conditions are met.
LivaNova PLC director William A. Kozy reported equity compensation-related transactions involving ordinary shares and restricted stock units. On June 15, 2026, previously vested RSUs were settled into 5,681 ordinary shares, and 682 of those shares were withheld to satisfy tax liability, leaving him with 37,566 ordinary shares held directly.
Kozy also received a new grant of 2,383 restricted stock units under the company’s 2025 Director Incentive Award Plan. These RSUs each represent a right to receive one ordinary share and are scheduled to vest on June 15, 2027, subject to continued service and the plan’s terms.
LivaNova PLC director Stacy Enxing Seng reported routine equity compensation activity. On June 15, 2026, vested restricted stock units were settled into 4,042 ordinary shares, classified as an option/RSU exercise. To cover related taxes, 486 ordinary shares were withheld at $79.70 per share rather than sold on the open market.
Following these transactions, she directly holds 15,307 ordinary shares. Enxing Seng also received a new grant of 2,383 restricted stock units under LivaNova’s 2025 Director Incentive Award Plan, which are scheduled to vest on June 15, 2027, subject to continued service and plan terms.
LivaNova PLC director Story Brooke reported routine equity compensation activity involving restricted stock units (RSUs) and related tax withholding. On June 15, 2026, 4,042 RSUs vested and were exercised into ordinary shares, and 486 of those shares were withheld to satisfy tax liabilities at a price of $79.70 per share.
Following these transactions, Brooke directly holds 9,788 ordinary shares. On the same date, Brooke also received a new grant of 2,383 RSUs under the company’s 2025 Director Incentive Award Plan, which are scheduled to vest on June 15, 2027, subject to continued service.
LivaNova PLC director Donald Zurbay reported routine equity compensation activity involving restricted stock units (RSUs). On June 15, 2026, vested RSUs were settled into 2,560 ordinary shares under the company’s 2025 Director Incentive Award Plan. To cover tax obligations, 308 ordinary shares were withheld at $79.70 per share, leaving Zurbay with 2,252 ordinary shares directly held after the transactions. He also received a new grant of 2,383 RSUs that each represent a right to receive one ordinary share and are scheduled to vest on June 15, 2027, subject to continued service.
LivaNova PLC director Francesco Bianchi sold shares of the company. On May 26, 2026, he executed an open-market sale of 1,800 Ordinary Shares at an average price of $75.75 per share. After this transaction, he directly holds 7,228 Ordinary Shares of LivaNova.
LivaNova PLC Chief Innovation Officer Ahmet Tezel reported routine equity compensation changes. Vested restricted stock units converted into 3,408 ordinary shares, with 1,186 shares withheld at $61.27 to cover taxes, leaving 4,157 ordinary shares held directly. Tezel also received 13,873 new restricted stock units and four performance stock unit awards of 4,624 units each, all subject to multi‑year vesting and performance conditions tied to revenue growth, relative total shareholder return, and adjusted earnings per share.
LivaNova PLC executive Franco Poletti, President of Cardiopulmonary, reported routine equity compensation activity involving vested restricted stock units (RSUs) settling into ordinary shares. On March 30, 2026, 3,184 ordinary shares were issued upon RSU vesting, with 1,370 shares withheld at 61.27 per share to cover tax liabilities.
After these transactions, Poletti held 10,755 ordinary shares directly, plus 219 ordinary shares held indirectly through his spouse. The RSUs vested under LivaNova’s 2015 Incentive Award Plan, 2022 Incentive Award Plan and the First Amended and Restated 2022 Incentive Award Plan, reflecting ongoing, scheduled compensation vesting rather than open‑market trading.
LivaNova PLC Chief Financial Officer Alex Shvartsburg reported multiple equity compensation events on March 30, 2026. Vested restricted stock units and performance stock units were settled in ordinary shares, and 30,835 ordinary shares were acquired through exercises. Of these, 12,868 shares were withheld at $61.27 per share to cover tax liabilities, leaving 44,647 ordinary shares held directly afterward.
Earlier performance-based grants vested above target, with awards tied to cumulative free cash flow, return on investment capital, and relative total shareholder return vesting at 122.0%, 118.71%, and 113.89% of target, respectively. New grants included 16,321 restricted stock units and several performance stock unit awards that will vest over future service and performance periods.
LivaNova PLC Chief Executive Officer Vladimir Makatsaria reported multiple equity compensation transactions. On March 30, 2026, vested restricted stock units were settled into 21,042 ordinary shares, increasing his direct holdings to 14,167 ordinary shares after shares were withheld for taxes.
The company withheld 11,159 ordinary shares at $61.27 per share to satisfy tax liabilities. Makatsaria also received new grants of 52,227 restricted stock units and three separate awards of 17,409 performance stock units each, tied to future revenue growth, relative total shareholder return, and adjusted earnings per share over performance periods through 2028.
LivaNova PLC executive Stephanie Bolton reported equity compensation activity involving restricted stock units (RSUs), performance stock units (PSUs), and ordinary shares. On March 30, 2026, she exercised vested RSUs and PSUs into ordinary shares of LivaNova PLC, consistent with the company’s incentive award plans.
These exercises delivered 17,815 ordinary shares, while 8,377 ordinary shares were withheld at $61.27 per share to satisfy tax obligations, leaving her with 22,189 ordinary shares held directly after the transactions. There were no open-market purchases or sales; the only disposition was tax withholding.
Bolton also received new equity awards on the same date, including 8,976 RSUs and several PSU grants that will vest based on future revenue growth, relative total shareholder return, and adjusted earnings per share performance through 2028–2029, subject to continued service and plan terms.
LivaNova PLC Chief Human Resources Officer Natalia Kozmina reported multiple equity compensation transactions. Vested restricted stock units were settled into 6,389 ordinary shares, with 1,374 shares withheld at $61.27 per share to cover tax liabilities.
She received new grants of 9,792 restricted stock units and three separate awards of 3,264 performance stock units each, tied to revenue growth, relative total shareholder return, and adjusted EPS performance for 2026–2028. Following these transactions, she directly holds 5,015 ordinary shares.
LivaNova PLC executive Franco Poletti, President of Cardiopulmonary, exercised 2,140 Stock Appreciation Rights that converted into the same number of ordinary shares at $57.60 per share. To cover the SAR base price and tax liabilities, 2,049 shares were withheld at $62.26 per share, leaving a net increase of 91 shares. Following these routine compensation-related transactions, Poletti holds 8,941 ordinary shares directly and 219 shares indirectly through his spouse. The F-code dispositions reflect share withholding for settlement and taxes, not open-market sales.
LivaNova PLC officer reports RSU vesting and share withholding for taxes. The President, Cardiopulmonary of LivaNova PLC reported the vesting and settlement of 967 restricted stock units into ordinary shares on 12/15/2025 at an exercise price of $0. On the same date, 416 ordinary shares were disposed of through share withholding at a price of $63.06 to satisfy tax liabilities related to the vesting.
After these transactions, the officer beneficially owns 8,850 ordinary shares directly and 219 ordinary shares indirectly through a spouse. The RSUs were originally granted on December 15, 2023 under the Amended and Restated LivaNova PLC 2022 Incentive Award Plan and vested over a two-year schedule ending December 15, 2025.
LivaNova PLC director reported share activity related to vested restricted stock units. On December 15, 2025, 2,355 ordinary shares were acquired at $0 upon the exercise of previously granted RSUs under the LivaNova PLC 2015 Incentive Award Plan. On the same date, 269 shares were disposed of at $63.06 to cover tax liabilities, leaving 2,086 ordinary shares beneficially owned directly after these transactions.
The RSUs were originally granted on December 15, 2024 with a one-year vesting schedule and were subject to forfeiture before vesting under the plan and award agreement.
LivaNova PLC senior vice president, chief legal officer and company secretary reported routine equity activity related to restricted stock units. On December 15, 2025, 2,254 RSUs vested and were settled in ordinary shares at an exercise price of $0, increasing her directly held stake. On the same date, 1,122 ordinary shares were withheld at $63.06 per share to cover tax obligations, leaving 6,798 ordinary shares held directly after the transactions. The underlying RSUs were originally granted on December 15, 2022, under the LivaNova PLC 2022 Incentive Award Plan with a four-year vesting schedule, and 2,253 RSUs remain beneficially owned following this vesting event.
LivaNova PLC director reports small share sale in Form 4 filing. A company director sold 250 ordinary shares of LivaNova PLC (LIVN) on 11/18/2025 at a price of $53.94 per share. After this transaction, the director beneficially owns 6,232 ordinary shares, held directly. This filing is a routine disclosure of insider activity required under securities regulations and does not by itself describe any change in the company’s operations or strategy.